IHIsabelle J Henskens

Isabelle J Henskens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isabelle J Henskens has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Annemiek Doeksen

    Department of Oncological Surgery, St Antonius Hospital, Nieuwegein, Utrecht, The Netherlands

    2 shared publications
  • Helena M Verkooijen

    Imaging Division Trial office, University Medical Centre Utrecht, Utrecht, The Netherlands

    2 shared publications
  • Assa Braakenburg

    Department of Plastic, Reconstructive and Hand Surgery, St. Antonius Hospital , Utrecht

    1 shared publication
  • Britt A M Jansen

    Division of Imaging and Oncology, University Medical Centre (UMC) Utrecht, Utrecht, the Netherlands; Department of Surgery, St. Antonius Hospital, Utrecht, the Netherlands

    1 shared publication
  • Claudia A Bargon

    Department of Oncological Surgery, St. Antonius Hospital , Utrecht

    1 shared publication
  • Danny A. Young Afat

    Department of Plastic, Reconstructive and Hand Surgery, Amsterdam University Medical Centre, Amsterdam, the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Fluorescence imaging using indocyanine green to identify sentinel lymph nodes during surgery for breast cancer (INFINITE): protocol for a hybrid effectiveness-implementation trial using a stepped-wedge cluster design

    by Isabelle J Henskens, Tessa L Dinger, Iza Stekelenburg, Lea M Dijksman, Helena M Verkooijen, Emily L Postma, Annemiek Doeksen, Henk J Schuijt, INFINITE Study Group

    Introduction: Sentinel lymph node biopsy (SLNB) is the standard procedure for axillary staging in clinically node-negative breast cancer. Traditionally, SLNB is performed using technetium-labelled ( 99m Tc) nanocolloid, with or without blue dye. However, both tracers have important limitations. Blue dye poses safety risks, while 99m Tc-nanocolloid introduces additional hospital visits, radiation exposure, logistical complexity and high costs. Indocyanine green (ICG) fluorescence is a non-radioactive alternative, offering real-time visualisation while addressing many limitations of traditional tracers. Yet, adoption of ICG-guided SLNB remains limited. This trial aims to guide the implementation of ICG-guided SLNB via axillary incision, evaluate its real-world effectiveness and inform conditions for nationwide scale-up. Methods and analysis: The INFINITE trial is a multicentre, hybrid effectiveness-implementation study employing a stepped-wedge cluster design across seven Dutch hospitals. Clusters sequentially transition from SLNB using 99m Tc-nanocolloid alone (Phase I) to ICG as the primary tracer and 99m Tc-nanocolloid as a within-patient control (Phase II), and finally to ICG alone (Phase III). The hybrid design enables evaluation of implementation outcomes (penetration, adoption, fidelity, appropriateness, feasibility, acceptability), intervention outcomes (effectiveness, safety, costs) and patient-reported experience (patient satisfaction). The primary outcome is penetration, the proportion of Phase III SLNB procedures performed with ICG alone. An integrated implementation approach combines the Grol and Wensing model (process model), the Consolidated Framework for Implementation Research (determinant framework) and Proctor’s outcomes framework (evaluation framework). Outcomes are assessed quantitatively, supplemented by an embedded mixed-methods component to explain variation in implementation across centres. Ethics and dissemination: Ethical approval was obtained from the Medical Research Ethics Committees United (6 November 2024; NL87551.100.24). Results will be submitted to open-access, peer-reviewed journals and presented at conferences focused on oncological or image-guided surgery. Implementation tools, including a clinical protocol, implementation guide, educational materials and patient information, will be developed to support national adoption. Trial registration number: NCT07146295 .


  • Open Access

    Effectiveness of a patient decision aid for women considering post-mastectomy breast reconstruction: randomized controlled trial

    by Britt A M Jansen, Isabelle J Henskens, Claudia A Bargon, Teun Teunis, Assa Braakenburg, Danny A Young-Afat, Helena M Verkooijen, Annemiek Doeksen

    Background: Post-mastectomy breast reconstruction (PMBR) improves quality of life, yet decisions regarding type and timing are complex, requiring careful consideration of risks, benefits, and personal preferences. Shared decision-making enhances satisfaction with reconstructive decisions, but some women experience difficulty participating effectively. This study evaluated the effectiveness of a PMBR-specific patient decision aid (pDA) compared with high-quality standard care. Methods: In this single-centre RCT, women eligible for PMBR were assigned in a 1:1 ratio to either standard care alone (control) or standard care and a pDA (intervention). Questionnaires were completed at baseline, after reconstructive decision, and at 1-year post-surgery. The primary outcome was decisional conflict after the decision. Secondary outcomes included measures for the decision-making process, patient-reported, and surgical outcomes. Between-group differences were analysed using t-tests, Mann–Whitney U tests, and chi-square tests. Mean differences (MD) with 95% confidence intervals quantified outcomes, while effect sizes were determined by Cohen’s d. Results: A total of 134 patients were enrolled (66 intervention, 68 control). Both groups reported consistently low decisional conflict (17 and 20 respectively). No significant differences were found in the primary (MD −2.8, 95% c.i., −8.4 to 2.8, Cohen’s d −0.18) or secondary outcomes immediately after reconstructive decision or 1-year post-surgery. Conclusion: In a population with access to high-quality multidisciplinary care, an online pDA for PMBR did not provide additional benefits over standard care. Both approaches effectively supported reconstructive decision-making, resulting in consistently low levels of decisional conflict. Trial registration number: NL-OMON28003 (NTR), NL7939 (NTR-new)